In the global pharmaceutical supply chain, one small Caribbean island punches far above its weight. The US jurisdiction of Puerto Rico – just 100 miles by 35 miles – out-exports every individual US state in biopharmaceuticals, shipping over USD 53 billion worth of medicines and medical devices annually to 120 countries. That’s more than twice…
Country Reports
Saudi Arabia is moving fast, thinking big and aiming high as it powers towards the goals set forth in its Vision 2030 national transformation plan. The astonishing pace and extent of change underway throughout the Kingdom is fuelling major progress within the realm of healthcare and life science. The Middle East’s largest country and its…
Mexico’s healthcare and life sciences sector is at a pivotal moment. As a country with deep manufacturing expertise, a rapidly evolving regulatory landscape, and a strategic position at the heart of North America, Mexico is both a regional powerhouse and a critical player in the global healthcare ecosystem. But with opportunity comes challenge, and 2025…
Legal & Regulatory
The Pharma Legal Handbook: Argentina answers essential questions about the legal and regulatory environment for pharmaceuticals in Argentina. It is a must-have for any company operating in the country or looking to enter the market. Prepared in association with Marval, O’Farrell & Mairal, a leading Argentine law firm, it should answer any questions linked to…
The Pharma Legal Handbook: Egypt answers essential questions about the legal and regulatory environment for pharmaceuticals in Egypt. It is a must-have for any company operating in the country or looking to enter the market. Prepared in association with Youssry Saleh, a leading Egyptian law firm, it should answer any questions linked to regulation, pricing,…
Market Access & Health Technology Assesment: Japan is a must-have asset for any company operating in Brazil or looking to enter the market. Prepared in association with Nishimura & Asahi, a leading Brazilian law firm.
InFocus
Hong Kong is rapidly transforming from a regional observer into an active force in cell and gene therapy. Long known as a bridge between China and the world, the city is already delivering “Made in Hong Kong” CAR-T therapies under clinical trial conditions and boasts Asia’s first university-led GMP-certified CGT manufacturing centre. With the enticing…
Tremendous scientific and social progress has transformed HIV/AIDS from a death sentence to a manageable chronic condition for many. However, the disease still kills 650,000 people every year with formidable societal, legal, and economic obstacles remaining to realising the ultimate quest of complete eradication. This dedicated InFocus, bringing together key stakeholders in the global HIV…
2023 was a year of transformative change and challenge across the global healthcare and life sciences industries. Drawing on PharmaBoardroom’s exclusive interviews and op-eds from across the world in 2023, our latest report tackles some of the year’s key regional trends. It includes everything from the landmark introduction of drug price negotiations in the US…
InFigures
Europe is home to a host of world-leading universal healthcare systems, globally relevant research institutions, and the headquarters of some of the globe’s biggest pharma companies. European science has long had a massive impact, not just for patients on the continent, but globally. However, in recent years Europe has lagged both North America as well…
PharmaBoardroom’s latest report, InFigures: Latin America 2024 features up-to-date datasets from the region’s leading pharma markets and regional production hubs. The combined Latin America and Caribbean market of USD 197 billion looks set to be the fastest growing in the world over the next few years. IQVIA estimates that the Latin American pharma market will…
PharmaBoardroom’s latest report, InFigures: Asia Pacific 2023 features up-to-date datasets from the region’s leading pharma markets and regional innovation hubs. Covering everything from population health to market growth, company rankings, innovation footprints, IPOs, and drug approvals, as well as market-specific executive insight from the PharmaBoardroom archives, this exclusive new report is an excellent jumping-off point…
